Sanjay Gupta Premieres ‘Weed 4: Pot vs. Pills’ on CNN


ATLANTA, GA – CNN Chief Medical Correspondent Dr. Sanjay Gupta will broadcast premiere the fourth part of his groundbreaking series ‘Weed: Pot vs. Pills’ on Sunday, April 29, at 8pm EDT, on news network CNN.

“Over 115 Americans die every day from opioid overdoses, more than those killed in car accidents, from breast cancer or even guns,” CNN said is a press release. “Nearly 2.5 million Americans struggle with opioid addiction, and though controversial, some people believe a potentially lifesaving solution may lie in medical marijuana.”


Gupta will speak to healthcare experts in pain management and addiction medicine to explore the opioid crisis that has devastated American communities for several years.

He also will interview NFL running back Mike James, who was addicted to pain medications after an injury. James has since treated his addiction and pain issues with cannabis, and is the first former player to ask the National Football League for an exemption to use medical cannabis, which is not allowed under current NFL policy.

During the segment, Gupta will also discuss the history of Schedule 1 drugs; the federal restriction that prohibits cannabis, effectively stalling comprehensive federal policy that would allow cannabis to be legitimized, researched, or industrialized.

“Weed 4: Pot vs. Pills” will stream live for subscribers on Sunday April 29th, via CNNgo (at and via CNNgo apps for Apple TV, Roku, Amazon Fire, Samsung Smart TV and Android TV) and on the CNN mobile apps for iOS and Android. The documentary will also be available the day after the broadcast premiere on demand via cable/satellite systems, CNNgo platforms and CNN mobile apps.

Beginning April 20th, “Weed 1-3” will also be available to stream.

In 2013, Dr. Gupta famously penned the op-ed, “Why I Changed my Mind of Weed.” The first segment of “Weed” followed the op-ed. Gupta’s coverage of cannabis oil use for pediatric epilepsy introduced CBD to the mainstream stage virtually overnight when he profiled the case of patient Charlotte Figi, and her namesake cannabis strain Charlotte’s Web.